Corline Biomedical AB Cash Flow Conversion Efficiency

Latest as of June 2026: 0.001x

Corline Biomedical AB cash flow conversion efficiency. Based on the latest financial reports, Corline Biomedical AB (CLBIO) has a cash flow conversion efficiency ratio of 0.001x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr122.00K ≈ $13.13K USD) by net assets (Skr99.00 Million ≈ $10.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Corline Biomedical AB (2013–2025)

Cash flow conversion efficiency of Corline Biomedical AB from 2013 to 2025. This chart illustrates how Corline Biomedical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Corline Biomedical AB stock price for real-time trading data and today's change.

Corline Biomedical AB Cash Flow Conversion Ratio Explained

Corline Biomedical AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Corline Biomedical AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Corline Biomedical AB ranked by their cash flow conversion efficiency. Also see CLBIO market cap for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Helixmith Co. Ltd KQ:084990	-0.010x
Inmax Holding Co Ltd TWO:1591	-0.116x
SIM Acquisition Corp. I Class A Ordinary Shares NASDAQ:SIMA	-0.045x
Sinher Technology Inc TW:4999	0.012x
Mister Spex SE F:MRX	0.007x
Blackboxstocks Inc NASDAQ:BLBX	-0.090x
Manhattan Bridge Capital Inc NASDAQ:LOAN	0.029x
Aimei Health Technology Co., Ltd Ordinary Share NASDAQ:AFJK	-0.020x

Annual Cash Flow Conversion Efficiency for Corline Biomedical AB (2013–2025)

The table below shows the annual cash flow conversion efficiency of Corline Biomedical AB from 2013 to 2025. Review Corline Biomedical AB (CLBIO) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr93.76 Million ≈ $10.09 Million	Skr-17.69 Million ≈ $-1.90 Million	-0.189x	-89.81%
2024-12-31	Skr86.91 Million ≈ $9.35 Million	Skr-8.64 Million ≈ $-929.69K	-0.099x	-1146.88%
2023-12-31	Skr93.32 Million ≈ $10.04 Million	Skr886.00K ≈ $95.35K	0.009x	+113.92%
2022-12-31	Skr94.59 Million ≈ $10.18 Million	Skr-6.45 Million ≈ $-694.34K	-0.068x	-30.12%
2021-12-31	Skr92.23 Million ≈ $9.93 Million	Skr-4.83 Million ≈ $-520.32K	-0.052x	+46.16%
2020-12-31	Skr52.03 Million ≈ $5.60 Million	Skr-5.07 Million ≈ $-545.18K	-0.097x	+58.27%
2019-12-31	Skr59.32 Million ≈ $6.38 Million	Skr-13.84 Million ≈ $-1.49 Million	-0.233x	-212.44%
2018-12-31	Skr54.96 Million ≈ $5.91 Million	Skr-4.10 Million ≈ $-441.66K	-0.075x	+31.11%
2017-12-31	Skr45.93 Million ≈ $4.94 Million	Skr-4.98 Million ≈ $-535.71K	-0.108x	+41.76%
2016-12-31	Skr38.75 Million ≈ $4.17 Million	Skr-7.21 Million ≈ $-776.02K	-0.186x	+6.53%
2015-12-31	Skr21.25 Million ≈ $2.29 Million	Skr-4.23 Million ≈ $-455.34K	-0.199x	+52.91%
2014-12-31	Skr5.48 Million ≈ $590.25K	Skr-2.32 Million ≈ $-249.55K	-0.423x	-22.53%
2013-12-31	Skr8.00 Million ≈ $860.60K	Skr-2.76 Million ≈ $-296.95K	-0.345x	--

About Corline Biomedical AB

ST:CLBIO Sweden Biotechnology

Market Cap

$38.67 Million

Skr359.33 Million SEK

Market Cap Rank

#22639 Global

#427 in Sweden

Share Price

Skr13.75

Change (1 day)

-0.72%

52-Week Range

Skr13.60 - Skr19.80

All Time High

Skr28.20